ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
Delayed Nasdaq  -  04:00 2022-08-09 pm EDT
11.21 USD   -4.11%
08/04BTIG Adjusts Price Target for Adaptive Biotechnologies to $17 From $25, Maintains Buy Rating
MT
08/03ADAPTIVE BIOTECHNOLOGIES : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/03ADAPTIVE BIOTECHNOLOGIES : Q2 2022 Earnings Presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Adaptive Biotechnologies : Q2 2022 Earnings Presentation

08/03/2022 | 05:19pm EDT

Second Quarter 2022

Earnings Conference Call

Safe Harbor

This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements are neither historical facts nor

assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and other future conditions. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. All statements, other than statements of historical facts, contained in this presentation are forward looking statements, including statements regarding the ability to map adaptive immune responses to target disease states, the ability to leverage any such findings to advance solutions to diagnose, treat and prevent infectious diseases; regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective products and product candidates; FDA clearance or authorization of any products; planned non-IDE clinical studies, clinical trials and preclinical activities, research and development costs, current and prospective collaborations; the estimated size of the market for our products and product candidates; the timing and success of our development and commercialization of current products and product candidates; the availability of alternative therapies for our target markets; and the other risks and uncertainties described in our filings with the Securities and Exchange Commission including the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K, including our most recent Annual Report on Form 10-K filed on February 15, 2022. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Risks and uncertainties could cause actual results to differ materially from those expressed in our forward- looking statements. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

2

Q2 2022 Key Highlights

Q2' 22 Rev

$43.7M

+13% Y/Y

+13% Q/Q

MRD Business

  • Significant clonoSEQ test volume growth of 53% vs prior year
  • Received Medicare coverage for clonoSEQ DLBCL
  • Signed new pan-portfolio agreement with pharma partner

Immune Medicine Business

  • Pharma partnerships across diseases increasing (123% growth vs prior year)
  • Genentech partnership on track with both shared and private products
  • Focus on pharma partnering, TCR antigen mapping and Drug Discovery opportunities, while deferring commercialization of T-Detect

Corporate

  • Focus on operational efficiencies to drive leverage
  • Pursuing non-dilutive financing opportunities

3

MRD Business: clonoSEQ clinical testing

  • Q2'22 test delivered volume +53% vs P/Y; +17% vs P/Q
    • 357 ordering accounts in Q2 (+44% vs P/Y)
    • 1,445 ordering HCPs in Q2 (+53% vs P/Y)
    • Unique patients tested increased (+56% vs P/Y)

clonoSEQ test volume

8,998

7,698

6,341

6,850

17%

5,897

12%

8%

5,300

8%

11%

8,178

5,928

6,356

7,164

5,475

4,757

Q1'21

Q2'21

Q3'21

Q4'21

Q1'22

Q2'22

ASP ~$800

~$950-$1000

clonoSEQ tech transfer volume from international sites

ASP expected to grow in the low-mid single digits

4

Solidifying Adaptive's leadership in lymphoid cancers

400K patients

Expand

Received Medicare coverage (DLBCL)

into NHL

Preparing launch (DLBCL)

Multiple Myeloma

• MM in blood contributed 20% of MM Y/Y growth

in blood

• Expect MM data in blood by YE

Market expansion in

• 11% of Q2 orders from community

community

• 20% Q/Q growth in community accounts

Penetrate deeper in

• 72% of Q2 growth vs P/Y from established

institutional accounts

institutional accounts

Driven by sales force expansion

+

Future integration into customer ordering systems

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Adaptive Biotechnologies Corporation published this content on 03 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2022 21:13:09 UTC.


© Publicnow 2022
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
08/04BTIG Adjusts Price Target for Adaptive Biotechnologies to $17 From $25, Maintains Buy R..
MT
08/03ADAPTIVE BIOTECHNOLOGIES : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/03ADAPTIVE BIOTECHNOLOGIES : Q2 2022 Earnings Presentation
PU
08/03ADAPTIVE BIOTECHNOLOGIES CORP Management's Discussion and Analysis of Financial Condit..
AQ
08/03ADAPTIVE BIOTECHNOLOGIES : Q2 Earnings Snapshot
AQ
08/03TRANSCRIPT : Adaptive Biotechnologies Corporation, Q2 2022 Earnings Call, Aug 03, 2022
CI
08/03Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Posts Q2 Revenue $43.7M
MT
08/03Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results
GL
08/03Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results
AQ
08/03Adaptive Biotechnologies Corporation Reports Earnings Results for the Second Quarter an..
CI
More news
Analyst Recommendations on ADAPTIVE BIOTECHNOLOGIES CORPORATION
More recommendations
Financials (USD)
Sales 2022 188 M - -
Net income 2022 -229 M - -
Net cash 2022 144 M - -
P/E ratio 2022 -7,13x
Yield 2022 -
Capitalization 1 602 M 1 602 M -
EV / Sales 2022 7,74x
EV / Sales 2023 6,37x
Nbr of Employees 858
Free-Float 98,3%
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 11,21 $
Average target price 14,58 $
Spread / Average Target 30,1%
EPS Revisions
Managers and Directors
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Tycho W. Peterson Chief Financial Officer
Harlan Robins Chief Scientific Officer
R. Mark Adams Chief Operating & Technical Officer
Sector and Competitors